Document Detail

Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
MedLine Citation:
PMID:  20674999     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND AND AIMS: Intensive statin therapy represents an effective option after acute coronary syndromes (ACS). Despite evidence, switching to less effective statins frequently occurs in practice. Aim of this observational study was to assess the impact of switching from intensive to moderate statin therapy on clinical outcomes after ACS.
METHODS AND RESULTS: A cohort of 1321 consecutive ACS patients (886 men, age 71±.8years) discharged on atorvastatin 80mg/d in a 6.5year period was followed for 12months after discharge. During follow-up, 557 patients (42%) were switched by primary care physicians to moderate statin therapy, either for side effects (56%) or for safety concerns (44%). No major adverse reaction was reported. Increasing age (HR 1.52 per 10-year increase, 95% CI 1.23-1.78, p=0.01), and female gender (HR 1.11, 95% CI 1.06-1.23, p=0.02) were associated with a higher probability of switch. Patients following a cardiac rehabilitation program (HR 0.64 95% CI 0.49-0.86, p=0.02) and diabetic subjects (HR 0.81, 95% CI 0.67-0.92, p=0.02) were more likely to continue atorvastatin 80mg/d. During follow-up, a major adverse clinical event occurred in 331 patients (one-year probability 0.25, 95% CI 0.22-0.27). Multivariate analysis with Cox proportional hazards method, including statin switching as a time-dependent covariate, demonstrated that, after adjustment for demographic and clinical variables, reduction from intensive to moderate statin therapy was an independent predictor of adverse clinical outcomes (HR 2.7, 95% CI 1.7-5.1, p=0.004).
CONCLUSION: Switching from intensive to moderate statin therapy after ACS is associated with an increased incidence of adverse clinical events.
Furio Colivicchi; Marco Tubaro; Massimo Santini
Related Documents :
21029819 - Impact of baseline plaque components on plaque progression in nonintervened coronary se...
11241029 - Treatment of wilson's disease with zinc xvi: treatment during the pediatric years.
14624049 - Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin.
17186279 - Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin.
20350769 - Long-term changes in serum cholesterol level does not influence the progression of coro...
9523539 - Ldl apheresis for arteriosclerosis obliterans with occluded bypass graft: change in pro...
23162959 - Expectations and outcome of a scientifically developed hip prosthesis in 170 hips with ...
20364569 - Malnutrition-inflammation score associated with atherosclerosis, inflammation and short...
21319129 - Early cannulation prosthetic graft (flixenetm) for arteriovenous access.
Publication Detail:
Type:  Journal Article     Date:  2010-08-01
Journal Detail:
Title:  International journal of cardiology     Volume:  152     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  56-60     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mortality in adult congenital heart disease: Are national registries reliable for cause of death?
Next Document:  The prevalence and risk factors for cholelithiasis and asymptomatic gallstones in adults with congen...